ES2774267T3 - Compuestos inhibidores de metaloenzimas - Google Patents

Compuestos inhibidores de metaloenzimas Download PDF

Info

Publication number
ES2774267T3
ES2774267T3 ES13738427T ES13738427T ES2774267T3 ES 2774267 T3 ES2774267 T3 ES 2774267T3 ES 13738427 T ES13738427 T ES 13738427T ES 13738427 T ES13738427 T ES 13738427T ES 2774267 T3 ES2774267 T3 ES 2774267T3
Authority
ES
Spain
Prior art keywords
compound
disease
mmol
agent
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13738427T
Other languages
English (en)
Spanish (es)
Inventor
William J Hoekstra
Robert J Schotzinger
Stephen W Rafferty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mycovia Pharmaceuticals Inc
Original Assignee
Mycovia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mycovia Pharmaceuticals Inc filed Critical Mycovia Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2774267T3 publication Critical patent/ES2774267T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13738427T 2012-01-20 2013-01-18 Compuestos inhibidores de metaloenzimas Active ES2774267T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261589076P 2012-01-20 2012-01-20
PCT/US2013/022313 WO2013109998A1 (en) 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds

Publications (1)

Publication Number Publication Date
ES2774267T3 true ES2774267T3 (es) 2020-07-20

Family

ID=48799718

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13738427T Active ES2774267T3 (es) 2012-01-20 2013-01-18 Compuestos inhibidores de metaloenzimas

Country Status (14)

Country Link
US (3) US10221160B2 (show.php)
EP (1) EP2804858B1 (show.php)
JP (1) JP6189865B2 (show.php)
KR (1) KR102061137B1 (show.php)
CN (1) CN104136427B (show.php)
AU (2) AU2013209516A1 (show.php)
BR (1) BR112014017751B1 (show.php)
CA (1) CA2861339C (show.php)
DK (1) DK2804858T3 (show.php)
EA (1) EA026209B1 (show.php)
ES (1) ES2774267T3 (show.php)
IN (1) IN2014DN06792A (show.php)
PL (1) PL2804858T3 (show.php)
WO (1) WO2013109998A1 (show.php)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2839769A1 (en) * 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2013209516A1 (en) * 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
AU2015231234B2 (en) * 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
JP6606508B2 (ja) * 2014-03-19 2019-11-13 マイコヴィア ファーマシューティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
MX371291B (es) 2014-03-19 2020-01-24 Viamet Pharmaceuticals Nc Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion.
AU2015231220B2 (en) * 2014-03-19 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antifungal compound process
JP6572234B2 (ja) * 2014-03-19 2019-09-04 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
EA037587B1 (ru) 2014-03-19 2021-04-19 Майковиа Фармасьютикалс, Инк. Способ получения противогрибковых соединений
JP6518683B2 (ja) * 2014-03-19 2019-05-22 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
MX382905B (es) 2014-03-19 2025-03-13 Viamet Pharmaceuticals Nc Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)-3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
JP2017514790A (ja) * 2014-03-19 2017-06-08 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
AU2015231270B2 (en) * 2014-03-19 2019-03-07 Viamet Pharmaceuticals (NC), Inc. Antifungal compound process
CA2978339C (en) * 2015-03-19 2021-08-03 Viamet Pharmaceuticals, Inc. Antifungal compounds and processes for making
MX391538B (es) 2015-09-18 2025-03-21 Mycovia Pharmaceuticals Inc Proceso de compuesto antifungico.
WO2017117393A1 (en) 2015-12-30 2017-07-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
ES2970715T3 (es) 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Composiciones y métodos para inhibir la actividad de la arginasa
CN109666019B (zh) * 2017-10-14 2021-04-06 朱允涛 一种氘代的氮唑醇类化合物及其制备方法和用途
CN109810049B (zh) * 2018-11-30 2021-01-15 深圳大学 一种含吡啶的化合物及其提取方法
WO2021143811A1 (zh) * 2020-01-17 2021-07-22 上海森辉医药有限公司 四氮唑类化合物的可药用盐及其结晶形式、制备方法和用途
EP4228628A4 (en) * 2020-10-16 2024-10-30 Miralogx LLC METALLOENZYME INHIBITORS FOR THE TREATMENT OF CANCER, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS AND OTHER DISORDERS

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8304282D0 (en) * 1983-02-16 1983-03-23 Pfizer Ltd Antifungal agents
GB8305377D0 (en) 1983-02-25 1983-03-30 Pfizer Ltd Antifungal agents
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
GB8415889D0 (en) 1984-06-21 1984-07-25 Ici Plc Antifungal azole compounds
AU4327585A (en) 1984-06-21 1986-01-02 Imperial Chemical Industries Plc Antifungal azole compounds
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ATE107176T1 (de) 1989-12-04 1994-07-15 Searle & Co System zur transdermalen albuterol applikation.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
GB9121456D0 (en) * 1991-10-10 1991-11-27 Pfizer Ltd Triazole antifungal agents
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5358939A (en) 1992-06-25 1994-10-25 Rohm And Haas Company Fungicidal 2-aryl-2,2-disubstituted ethyl-1,2,4-triazoles
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
MY115814A (en) 1995-06-16 2003-09-30 Bayer Ip Gmbh Crop protection compositions
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
JP2000344744A (ja) * 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
KR100959404B1 (ko) 2006-10-18 2010-05-25 이인환 치아 근관충전용 근관치료기 및 그의 발열팁
JP2010510248A (ja) 2006-11-21 2010-04-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分をターゲティング部分と組み合わせて使用する金属酸化還元酵素阻害剤
US8221057B2 (en) 2008-06-25 2012-07-17 General Electric Company Method, system and controller for establishing a wheel space temperature alarm in a turbomachine
KR20110048586A (ko) 2008-09-03 2011-05-11 바이엘 크롭사이언스 아게 특정 녹병균을 구제하기 위한 살진균성 조성물의 용도
AU2010339508B2 (en) * 2009-12-31 2016-02-04 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP5266430B2 (ja) * 2010-04-24 2013-08-21 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
AU2011320565A1 (en) * 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
ES2703498T3 (es) * 2010-11-13 2019-03-11 Innocrin Pharmaceuticals Inc 1-(6,7-Bis(difluorometoxi)naftalen-2-il)-2-metil-1-(1H-1,2,3-triazol-4-il)propan-1-ol como inhibidor de CYP17 para el tratamiento de enfermedades dependientes de andrógenos como el cáncer de próstata
BR112013014484A2 (pt) * 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
CA2839769A1 (en) * 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2839691A1 (en) * 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2012273007A1 (en) * 2011-06-23 2014-01-30 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
CA2846117A1 (en) * 2011-08-30 2013-03-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2788343B1 (en) * 2011-12-11 2018-02-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
EA201491386A1 (ru) * 2012-01-20 2014-11-28 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
AU2013209516A1 (en) * 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
EP2948450A4 (en) * 2013-01-28 2016-11-09 Viamet Pharmaceuticals Inc METALLOENZYMINHIBITORVERBINDUNGEN
EA201690007A1 (ru) * 2013-06-12 2016-04-29 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
JP2017513848A (ja) * 2014-04-15 2017-06-01 ダウ アグロサイエンシィズ エルエルシー 殺真菌剤としての金属酵素阻害剤化合物
WO2015160664A1 (en) * 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
DK3562487T3 (da) * 2016-12-29 2024-01-02 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloenzyminhibitorforbindelser

Also Published As

Publication number Publication date
US10221160B2 (en) 2019-03-05
DK2804858T3 (da) 2020-03-16
JP2015504095A (ja) 2015-02-05
AU2017232080A1 (en) 2017-10-12
US11247981B2 (en) 2022-02-15
CN104136427B (zh) 2017-03-01
US20150004666A1 (en) 2015-01-01
AU2013209516A1 (en) 2014-08-28
US10526312B2 (en) 2020-01-07
WO2013109998A1 (en) 2013-07-25
EP2804858B1 (en) 2019-12-25
CN104136427A (zh) 2014-11-05
US20200247779A1 (en) 2020-08-06
IN2014DN06792A (show.php) 2015-05-22
KR102061137B1 (ko) 2019-12-31
AU2017232080B2 (en) 2019-02-14
CA2861339C (en) 2020-08-25
CA2861339A1 (en) 2013-07-25
EP2804858A1 (en) 2014-11-26
EA201491385A1 (ru) 2015-02-27
BR112014017751A8 (pt) 2021-03-09
US20190169159A1 (en) 2019-06-06
PL2804858T3 (pl) 2020-06-29
JP6189865B2 (ja) 2017-08-30
EA026209B1 (ru) 2017-03-31
EP2804858A4 (en) 2015-07-29
KR20140116939A (ko) 2014-10-06
BR112014017751B1 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
ES2774267T3 (es) Compuestos inhibidores de metaloenzimas
ES2563319T3 (es) Compuestos inhibidores de metaloenzimas
DK2788343T3 (en) METALLOENZYMIN INHIBITOR COMPOUNDS
EA036098B1 (ru) Способ получения противогрибковых соединений